Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, and sale of prescription pharmaceutical products in the United States. The company’s products focus on women’s health, as well as central nervous system disorders, including attention deficit hyperactivity disorder (ADHD). Its products include Brisdelle, a non-hormonal therapy for vasomotor symptoms associated with menopause; Minivelle, an estrogen therapy patch for the treatment of vasomotor symptoms due to menopause and prevention of post-menopausal osteoporosis; CombiPatch, an estradiol/norethindrone acetate transdermal system to treat symptoms of hot flashes, and vaginal dryness associated with meno...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Executive Officer and Director
Chief Financial Officer, Vice President and Treasurer
Vice President of Operations
Chief Medical Officer and Executive Vice President of Product Development
Vice President, General Counsel and Corporate Secretary
Compensation as of Fiscal Year 2016.
Noven Pharmaceuticals, Inc. Key Developments
Noven Pharmaceuticals, Inc. Appoints Jeff Mihm to Board of Directors
Sep 14 16
Noven Pharmaceuticals, Inc. has announced the appointment of Jeff Mihm to its board of directors. Mr. Mihm, who currently serves as Noven's CEO, brings extensive industry and business experience to the new, expanded role. Prior to his appointment as Noven's CEO in January 2016, Mr. Mihm most recently served as Noven's vice president, Chief Administrative Officer & General Counsel, where he oversaw Business Development, Corporate Affairs, Human Resources, Information Technology and Legal/Compliance functions. Prior to joining Noven in 2003, Mr. Mihm was a corporate attorney for more than 10 years, including as a partner in a national law firm.
Noven Pharmaceuticals, Inc. Reaches Agreement with Sebela International Limited to Assign Rights of Approval for Manufacture, Commercialization and Associated Intellectual Property for Brisdelle Capsules and Pexeva Tablets
Jul 26 16
Hisamitsu Pharmaceutical Co., Inc. announced that its wholly owned subsidiary in the United States, Noven Pharmaceuticals, Inc. has reached agreement with Sebela International Limited to assign rights of approval for manufacture, commercialization and associated intellectual property for Brisdelle (Paroxetine) Capsules, 7.5 mg and Pexeva (Paroxetine Mesylate) Tablets to Sebela.
Noven Pharmaceuticals, Inc. Announces Executive Changes
Mar 7 16
Noven Pharmaceuticals, Inc. announced the appointment of Dolores Calicchio as the company's new Vice President of Human Resources, succeeding Lance Williams, who will be retiring in April. In this role, Calicchio will lead and be responsible for all human resources activities impacting Noven's workforce across the U.S. Prior to joining Noven, Calicchio served as the Vice President of Human Resources at Carnival Cruise Lines. As Noven's Vice President of Human Resources, Calicchio will report directly to Noven's Chief Executive Officer, Jeff Mihm. Regarding Calicchio's appointment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|